Eloxx Pharmaceuticals Inc. Stock News

Wall Street securities analysts on Friday revised their ratings and price targets on several U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings. HIGHLIGHTS

Q1 2020 Eloxx Pharmaceuticals Inc Earnings Call

Completing our Phase 2 clinical trial program for ELX-02 in Cystic Fibrosis remains our highest priority Preclinical studies advancing in autosomal dominant polycystic kidney.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) Adverum Biotechnologies Inc...

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

Bank of New York Mellon Corp grew its stake in shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) by 7.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange

Shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) have earned a consensus recommendation of “Buy” from the six ratings firms that are covering the company, Marketbeat reports. Two investment analysts

The Zacks Analyst Blog Highlights: Eloxx Pharmaceuticals, BGC Partners, SharpSpring, Ra Medical Systems and American States Water

The Zacks Analyst Blog Highlights: Eloxx Pharmaceuticals, BGC Partners, SharpSpring, Ra Medical Systems and American States Water

These five stocks are poised to grow with the guidelines laid out to reopen the economy, as coronavirus pandemic dissipates.

These five stocks are poised to grow with the guidelines laid out to reopen the economy, as coronavirus pandemic dissipates.

Looking at the price chart, it is interesting to note that Vertex has a key resistance level at around $250, and it looks like it wants to break above such a level in the short term.

Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by no

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET

Renaissance Technologies LLC lifted its stake in Eloxx Pharmaceuticals (OTCMKTS:ELOX) by 572.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange